Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

Diabetes Care
Michael J HallerType 1 Diabetes TrialNet ATG-GCSF Study Group

Abstract

A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor (GCSF) preserves C-peptide in established type 1 diabetes (T1D) (duration 4 months to 2 years). We hypothesized that 1) low-dose ATG/GCSF or 2) low-dose ATG alone would slow the decline of β-cell function in patients with new-onset T1D (duration <100 days). A three-arm, randomized, double-masked, placebo-controlled trial was performed by the Type 1 Diabetes TrialNet Study Group in 89 subjects: 29 subjects randomized to ATG (2.5 mg/kg intravenously) followed by pegylated GCSF (6 mg subcutaneously every 2 weeks for 6 doses), 29 to ATG alone (2.5 mg/kg), and 31 to placebo. The primary end point was mean area under the curve (AUC) C-peptide during a 2-h mixed-meal tolerance test 1 year after initiation of therapy. Significance was defined as one-sided P value < 0.025. The 1-year mean AUC C-peptide was significantly higher in subjects treated with ATG (0.646 nmol/L) versus placebo (0.406 nmol/L) (P = 0.0003) but not in those treated with ATG/GCSF (0.528 nmol/L) versus placebo (P = 0.031). HbA1c was significantly reduced at 1 year in subjects treated with ATG and ATG/GCSF, P = 0.002 and 0.01...Continue Reading

Associated Clinical Trials

References

Sep 8, 1988·The New England Journal of Medicine·J SilversteinS Johnson
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Nov 25, 2003·Diabetes Care·Desmond SchatzMark A Atkinson
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity·Michael J HallerDesmond A Schatz
Jan 20, 2009·Nature Biotechnology·Yoshimi KuroiwaJames M Robl
Nov 27, 2009·The New England Journal of Medicine·Mark D PescovitzUNKNOWN Type 1 Diabetes TrialNet Anti-CD20 Study Group
Feb 3, 2012·The New England Journal of Medicine·Johnny LudvigssonSabine Baron
Jul 31, 2013·Lancet·Mark A AtkinsonAaron W Michels
Sep 13, 2013·Diabetes Care·Mark D PescovitzUNKNOWN Type 1 Diabetes TrialNet Anti-CD20 Study Group
Dec 4, 2013·Diabetes Care·Tihamer OrbanUNKNOWN Type 1 Diabetes TrialNet Abatacept Study Group
Dec 17, 2014·The Journal of Clinical Investigation·Jay S Skyler
Dec 17, 2014·The Journal of Clinical Investigation·Michael J HallerDesmond A Schatz
Nov 5, 2016·Diabetes/metabolism Research and Reviews·Brian N BundyUNKNOWN Type 1 Diabetes TrialNet Study Group
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Oct 27, 2018·Diabetic Medicine : a Journal of the British Diabetic Association·P A Senior, J H Pettus
Apr 27, 2019·Annals of the New York Academy of Sciences·Tijana Martinov, Brian T Fife
Jun 25, 2019·Expert Review of Proteomics·Ernesto S NakayasuThomas O Metz
Jul 17, 2019·Clinical and Experimental Immunology·L PetersT M Brusko
Sep 27, 2019·Clinical and Experimental Immunology·W HaoC J Greenbaum
Jan 9, 2020·The Journal of Clinical Endocrinology and Metabolism·Cate SpeakeCarmella Evans-Molina
Aug 28, 2020·Scandinavian Journal of Immunology·Bergithe E Oftedal, Anette S B Wolff
Sep 1, 2018·Current Diabetes Reports·Laura M JacobsenTodd M Brusko
Oct 26, 2018·Frontiers in Medicine·Ken Coppieters, Matthias von Herrath
Sep 29, 2019·International Journal of Molecular Sciences·Miriam Cabello-OlmoMiguel Barajas
Sep 29, 2019·Diabetes Care·Emily K SimsUNKNOWN Type 1 Diabetes TrialNet Study Group
Jul 25, 2020·Endocrinology, Diabetes & Metabolism·Brian N BundyUNKNOWN Type 1 Diabetes TrialNet Study Group
Mar 25, 2019·Frontiers in Immunology·Maki Nakayama, Aaron W Michels
Feb 19, 2020·Diabetes Technology & Therapeutics·Bimota NambamDesmond Schatz
Jul 17, 2020·Frontiers in Endocrinology·Marina PrimaveraFrancesco Chiarelli
Nov 13, 2019·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Alberto Sánchez-FueyoGiovanna Lombardi
Jan 27, 2020·Diabetologia·John M WentworthLeonard C Harrison
Aug 21, 2020·The Journal of Clinical Investigation·Yuqing LiuDefu Zeng
Dec 17, 2019·Cell Metabolism·Jeremy T WarshauerMark S Anderson
Aug 25, 2020·Diabetes Technology & Therapeutics·Laura M JacobsenMichael J Haller
Feb 18, 2021·Diabetologia·Bernt Johan von ScholtenMatthias von Herrath
Mar 5, 2021·Science Translational Medicine·Emily K SimsUNKNOWN Type 1 Diabetes TrialNet Study Group
Mar 18, 2021·Reviews in Endocrine & Metabolic Disorders·Natalia G VallianouMaria Dalamaga
Jun 7, 2021·Current Opinion in Endocrinology, Diabetes, and Obesity·Laura M Jacobsen, Desmond A Schatz
Jul 31, 2021·Science·Jeffrey A BluestoneKevan C Herold
Sep 24, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·Danijela Tatovic, Colin M Dayan
Dec 12, 2021·British Medical Bulletin·L A Allen, C M Dayan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.